Med. praxi. 2021;18(2):123-127 | DOI: 10.36290/med.2021.020

Venoactive drug therapy in surgical or endovenous treatment for varicose veins

MUDr. Robert Vlachovský, Ph.D.
II. chirurgická klinika, Centrum cévních onemocnění, FN u sv. Anny v Brně a Lékařská fakulta Masarykovy univerzity, Brno

Lower limb varicose veins can be treated with endovenous ablation procedures or with minimally invasive open techniques. We investigated whether venoactive drugs used to treat chronic venous disease (CVD), provide benefits to patients undergoing or recovering from a varicose vein procedure. We conducted a systematic review of the literature to identify clinical trials investigating venoactive drugs therapy before, during, or after a surgical, endovenous, or sclerotherapy procedure for varicose veins. We identified five clinical trials investigating the effects of venoactive drugs on recovery after interventions. All studies reported the use of micronized purified flavonoid fraction (MPFF), in one study, sulodexide was also used. Three studies reported significantly less post-procedural pain with MPFF treatment, two studies reported significant reductions in post-procedural bleeding with MPFF treatment. Three studies reported greater symptomatic improvement with MPFF treatment. Venoactive drugs therapy may help reduce post-procedural pain, hemorrhage, and CVD specific symptoms. New randomized studies are needed to clearly demonstrate the benefits and advantages mentioned above.

Keywords: varicose veins, chronic venous disease, varicose veins surgery, endovenous procedures, sclerotherapy, venoactive drugs.

Published: April 30, 2021  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Vlachovský R. Venoactive drug therapy in surgical or endovenous treatment for varicose veins. Med. praxi. 2021;18(2):123-127. doi: 10.36290/med.2021.020.
Download citation

References

  1. Bergan JJ, Schmid-Schönbein GW, Smith PD, et al. Chronic venous disease. N Engl J Med 2006; 355: 488-498. Go to original source... Go to PubMed...
  2. Roztočil K. Co nového je ve farmakoterapii žilních onemocnění. Interní Med. 2014; 16(1): 5-10.
  3. Fowkes FG, Lee AJ, Evans CJ, et al. Lifestyle risk factors for lower limb venous reflux in the general population: Edinburgh Vein Study. Int J Epidemiol 2001; 30: 846-852. Go to original source... Go to PubMed...
  4. Karetová D. Farmakologická léčba chronické žilní nemoci. In: Ambrózy E, Chochola M, Karetová D. Angiologie 2009, pokroky v angiologii. Maxdorf 2009: 155.
  5. Rabe E, Guex JJ, Puskas A, et al. Epidemiology of chronic venous disorders in geographically diverse populations: results from the Vein Consult Program. Int Angiol 2012; 31: 105-115. Go to PubMed...
  6. Mansilha A, Sousa J. Pathophysiological mechanisms of chronic venous disease and implications for venoactive drug therapy. Int. J. Mol. Sci. 2018; 19(6): 1669. Go to original source... Go to PubMed...
  7. Nicolaides A, Kakkos S, Baekgaard N, et al. Management of chronic venous disorders of the lower limbs. Guidelines According to Scientific Evidence. Part I. Int Angiol 2018; 37: 181-254. Go to original source... Go to PubMed...
  8. Lurie F. Advanced Stages of Chronic Venous Disease: Evolution of Surgical Techniques and Advantages of Associated Medical Treatment. Adv Ther. 2020 Feb; 37(Suppl1): 6-12. Go to original source... Go to PubMed...
  9. Vuylsteke ME, Klitfod L, Mansilha A. Endovenous ablation. Int Angiol 2019; 38: 22-38. Go to original source... Go to PubMed...
  10. Paravastu SC, Horne M, Dodd PD. Endovenous ablation therapy (laser or radiofrequency) or foam sclerotherapy versus conventional surgical repair for short saphenous varicose veins. Cochrane Database Syst Rev 2016; 11: CD010878. Go to original source... Go to PubMed...
  11. Coleridge Smith P. Foam and liquid sclerotherapy for varicose veins. Phlebology 2009; 24(Suppl 1): 62-72. Go to original source... Go to PubMed...
  12. Yiannakopoulou E. Safety concerns for sclerotherapy of telangiectases, reticular and varicose veins. Pharmacology 2016; 98: 62-69. Go to original source... Go to PubMed...
  13. Ramelet AA, Boisseau MR, Allegra C, et al. Veno-active drugs in the management of chronic venous disease. An international consensus statement: current medical position, prospective views and final resolution. Clin Hemorheol Microcirc 2005; 33: 309-319.
  14. Kakkos SK, Nicolaides AN. Efficacy of micronized purified flavonoid fraction (Daflon®) on improving individual symptoms, signs and quality of life in patients with chronic venous disease: a systematic review and meta-analysis of randomized double-blind placebo-controlled trials. Int Angiol 2018; 37: 143-154. Go to original source... Go to PubMed...
  15. Bogachev VY, Boldin BV, Lobanov VN. Benefits of micronized purified flavonoid fraction as adjuvant therapy on inflammatory response after sclerotherapy. Int Angiol 2018; 37: 71-78. Go to original source... Go to PubMed...
  16. Bogachev VY, Boldin BV, Turkin PY. Administration of Micronized Purified Flavonoid Fraction During Sclerotherapy of Reticular Veins and Telangiectasias: Results of the National, Multicenter, Observational Program VEIN ACT PROLONGED-C1. Adv Ther 2018; 35: 1001-1008. Go to original source... Go to PubMed...
  17. Bogachev VY, Golovanova OV, Kuznetsov AN, et al. Can Micronized Purified Flavonoid Fraction (MPFF) improve outcomes of lower extremity varicose vein endovenous treatment? First results from the DECISION study. Phlebolymphology 2013; 20(4): 181-187.
  18. Mazzaccaro D, Muzzarelli L, Modafferi A, et al. Use of venoactive drugs after surgery for varicose veins: a preliminary study. Int Angiol 2018; 37: 79-84. Go to original source... Go to PubMed...
  19. Saveljev VS, Pokrovsky AV, Kirienko AI, et al. Stripping of the great saphenous vein under micronized purified flavonoid fraction (MPFF) protection (results of the Russian multicenter controlled trial DEFANCE). Phlebolymphology 2008; 15(2): 45-51.
  20. Stoiko YM, Mazaishvili KV, Khlevtova TV, et al. [Effect of pharmacotherapy on course of postoperative period after endovenous thermal ablation]. Angiol Sosud Khir 2015; 21: 77-81.
  21. Veverková L, Kalač J, Jedlička V, et al. Analýza operačních výkonů na vena saphena magna v České republice a efekt Detralexu při jejím strippingu. Rozhl Chir 2005; 84: 410-412, 414-416.
  22. Martinez-Zapata MJ, Vernooij RW, Uriona Tuma SM, et al. Phlebotonics for venous insufficiency. Cochrane Database Syst Rev 2016; 4: CD003229. Go to original source... Go to PubMed...
  23. Nicolaides AN. The Benefits of Micronized Purified Flavonoid Fraction (MPFF) Throughout the Progression of Chronic Venous Disease. Adv Ther. 2020 Feb; 37(Suppl 1): 1-5. Go to original source... Go to PubMed...
  24. Carpentier P, van Bellen B, Karetova D, et al. Clinical efficacy and safety of a new 1000-mg suspension versus twice-daily 500-mg tablets of MPFF in patients with symptomatic chronic venous disorders: a randomized controlled trial. Int Angiol 2017; 36: 402-409. Go to original source... Go to PubMed...
  25. Kirienko A, Radak D. Clinical acceptability study of once-daily versus twice-daily micronized purified flavonoid fraction in patients with symptomatic chronic venous disease: a randomized controlled trial. Int Angiol 2016; 35: 399-405. Go to PubMed...
  26. Launois R. Health-related quality-of-life scales specific for chronic venous disorders of the lower limbs. J Vasc Surg Venous Lymphat Disord 2015; 3: 219-227. Go to original source... Go to PubMed...
  27. Mansilha A, Sousa J. Benefits of venoactive drug therapy in surgical or endovenous treatment for varicose veins: a systematic review. Int Angiol. 2019; 38(4): 291-298. Go to original source... Go to PubMed...




Medicine for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.